DrPISA Expands Proteomic Drug-Target Discovery

Identifying the proteins affected by a small molecule is central to mechanism-of-action studies, target deconvolution, and chemical proteomics. The reference study, DrPISA: Deep eutectic solvent-assisted reverse proteome-integrated solubility alteration for high-sensitivity drug target identification, addresses an important analytical blind spot: proteins that aggregate during thermal treatment are commonly excluded when workflows analyze only soluble fractions. The authors developed a deep eutectic solvent (DES)-assisted reverse proteome-integrated solubility alteration strategy to make these insoluble fractions measurable. The study is reported in Analytica Chimica Acta.

Study Background and Research Question

Thermal proteome profiling (TPP) and proteome integral solubility alteration (PISA) infer drug–protein interactions from changes in protein stability after heating. A ligand can stabilize or destabilize a protein, shifting its apparent solubility across a temperature series. TPP typically measures multiple temperature points separately and reconstructs melting behavior, whereas PISA pools soluble fractions from several temperatures to reduce sample handling and mass-spectrometry requirements.

However, the soluble fraction is not the complete thermal response. Some proteins, including potential drug targets, become highly aggregated after heating and remain in the pellet. Conventional reagents such as urea and guanidine hydrochloride can have limited ability to resolubilize these aggregates and may not provide an ideal environment for downstream digestion or quantitative proteomics. The research question was therefore practical and analytical: can a solvent system be identified that efficiently recovers heat-aggregated proteomes while preserving peptide generation and quantitative reproducibility?

Key Innovation from the Reference Study

DrPISA combines three ideas. First, it applies a systematic screen of DES formulations rather than assuming that a conventional chaotrope is optimal. Second, it analyzes the insoluble, heat-aggregated proteome through a reverse PISA design, complementing rather than replacing soluble-fraction profiling. Third, it incorporates a simplified dimethyl-labeling strategy that reduces the number of mass-spectrometry acquisitions needed for a multi-temperature experiment.

The selected reagent, DES-48, consisted of proline, glycerol, and water in a 1:1:4 ratio. In the study, this formulation improved aggregate resolubilization and digestion relative to urea and GuHCl. The innovation is not simply the use of a DES as a detergent-like additive. It is the integration of solvent selection, aggregate-focused sample preparation, thermal perturbation, and quantitative proteomics into a single target-identification workflow. This design expands the measurable drug-response space from soluble proteins to proteins whose most informative response is precipitation or aggregation.

Methods and Experimental Design Insights

The authors first evaluated 65 DES formulations for their ability to process heat-aggregated proteomes. The screening criteria included protein recovery, peptide identification, cleavage completeness, and quantitative reproducibility, as described in the reference study. This comparison-oriented design is valuable because solvent composition can influence not only protein dissolution but also enzymatic digestion, peptide recovery, chromatographic behavior, and mass-spectrometric compatibility.

Protocol Parameters

• DES screening: Sixty-five formulations were compared for recovery and downstream proteomic performance; these are literature-reported parameters from the reference workflow rather than universal optimization requirements.
• Selected solubilization reagent: DES-48 used proline:glycerol:water at a 1:1:4 ratio and was selected for processing heat-aggregated proteomes.
• Comparator reagents: DES-48 was benchmarked against urea and GuHCl to assess relative resolubilization, digestion, and identification performance.
• Thermal design: Reverse PISA examined insoluble fractions generated across six discrete heat treatments, allowing aggregation-associated stability changes to be quantified.
• Quantitative workflow: Samples from the six heat conditions were pooled before isotopic dimethyl labeling and quantitative mass spectrometry, a design intended to lower reagent use and instrument demand.
• Biological validation: Five reference compounds were used to test whether DrPISA could recover established targets and broaden protein-class coverage, with particular attention to kinases.

A notable design principle is the separation between sample-processing optimization and biological validation. The DES screen established that aggregate recovery was technically feasible; the compound experiments then tested whether the recovered proteins carried interpretable drug-response information. This reduces the risk of presenting improved peptide counts as equivalent to improved target discovery.

Core Findings and Why They Matter

DES-48 identified up to 71.7% more proteins than GuHCl and 23.5% more than urea in the reported comparisons. The workflow also produced 80.6% fully cleaved peptides and showed strong quantitative reproducibility. These results indicate that solvent selection affects the entire analytical chain, not merely the first step of dissolving a pellet. Better aggregate processing can increase the number of proteins that reach digestion and improve the quality of quantitative comparisons.

DrPISA also detected early aggregation-related stability changes that were not accessible through soluble-focused PISA. This is important because a subtle change in a protein's aggregation behavior may occur before a large soluble-fraction shift becomes statistically or biologically convincing. In this context, reverse PISA is best viewed as a complementary measurement layer that can uncover responses hidden by conventional fraction selection.

Across five reference compounds, the authors reproducibly recovered known targets and quantified 1,142 proteins. The dataset included 45 kinases, and DrPISA detected marginal kinase responses in staurosporine-treated samples that conventional PISA did not reveal. This finding supports the method's sensitivity claim while also illustrating a useful application boundary: the workflow can prioritize candidate interactions, but individual targets still require orthogonal validation.

The celastrol experiment provided the clearest biological demonstration. DrPISA identified LULL1 as a previously under-recognized interacting protein. The importance of this observation is methodological as much as biological. Expanding analysis into aggregated fractions can change the composition of the candidate-target list and may expose proteins that would otherwise be dismissed as technical losses. The result suggests that target deconvolution should consider both soluble and insoluble thermal responses when compound-induced aggregation is plausible.

Finally, the six-temperature dimethyl workflow reduced reagent consumption and mass-spectrometry acquisition time by more than 50% in the reported implementation. This makes the approach more scalable than a fully expanded temperature-by-temperature design, although the exact savings will depend on instrument configuration, multiplexing, and sample throughput.

Why this cross-domain matters, maturity, and limitations

The reference study belongs to analytical chemistry and chemical proteomics, while the available internal articles address experimental nephrology and toxicant-based renal injury models. Their relationship is therefore complementary rather than evidentiary: DrPISA supplies a strategy for discovering protein-level responses, whereas renal injury models supply biological systems in which those responses might be investigated. The provided evidence does not show that DrPISA was tested with a podocyte toxin or in a nephrotic-syndrome model, so conclusions should not be transferred directly across domains.

Comparison with Existing Internal Articles

The internal article on reproducible nephrotoxic renal modeling emphasizes proteinuria and glomerular lesions as readouts of experimental kidney injury. A second internal resource, on podocyte injury and FSGS-oriented mechanisms, focuses on mechanistic interpretation of glomerular pathology. Those discussions answer a different question from DrPISA: how to establish and interpret a renal injury phenotype rather than how to expand proteomic target coverage.

For researchers combining these areas, the defensible connection is at the experimental-design level. A renal injury model could provide a biologically relevant context for testing whether a treatment changes protein stability or aggregation, while DrPISA could broaden the proteins measured after thermal perturbation. Such a combined design would still require independent optimization of tissue or cell lysis, matrix effects, compound exposure, and validation of candidate interactions. The internal articles should therefore be read as disease-model context, not as validation of DrPISA performance.

Limitations and Transferability

Several limitations temper the study's implications. First, improved protein identification does not automatically mean improved target specificity. Aggregation can reflect direct ligand binding, secondary structural damage, abundance changes, complex dissociation, or nonspecific stress. Candidate proteins identified by DrPISA therefore require orthogonal confirmation, such as biochemical binding assays, genetic perturbation, or a suitably designed cellular response experiment.

Second, DES-48 was selected under the authors' experimental conditions. Its performance may vary with proteome composition, starting material, heating regime, protein concentration, digestion enzyme, cleanup procedure, and liquid-chromatography system. DES carryover or altered peptide behavior could also affect quantitative measurements if removal is incomplete. Laboratories should reproduce the relevant controls before treating the reported percentage gains as expected routine performance.

Third, the dimethyl-labeling simplification improves efficiency but may reduce the granularity available from a fully resolved thermal series. Pooling six conditions is useful for throughput and integrated quantification, yet it can obscure the shape of an individual protein's response curve. The method is consequently well suited to high-sensitivity screening and prioritization, while detailed melting behavior may require a complementary TPP-style experiment.

Finally, the study's evidence base centers on thermal aggregation and a limited set of reference compounds, including celastrol and staurosporine. Transfer to membrane proteins, poorly soluble complexes, tissue lysates, or highly heterogeneous disease samples remains an empirical question. DrPISA is best understood as a complementary extension of PISA, not a universal replacement for soluble-proteome assays.

Research Support Resources

For nephrology experiments that use proteomics alongside a podocyte injury model, glomerular lesion induction, a focal segmental glomerulosclerosis (FSGS) model, or proteinuria induction in animal models, researchers can use Puromycin aminonucleoside (SKU A3740). This aminonucleoside moiety of puromycin is used as a nephrotoxic agent for nephrotic syndrome research; the product information describes its application in podocyte injury and experimental glomerular pathology. It can provide a biological injury context for complementary proteomic studies, but DrPISA-specific compatibility should be established experimentally.